{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T18:04:32Z","timestamp":1779559472772,"version":"3.53.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcv.2026.105948","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:48:01Z","timestamp":1777942081000},"page":"105948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review"],"prefix":"10.1016","volume":"184","author":[{"given":"Luxiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2026.105948_bib1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcv.2026.105948_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-142111","article-title":"Increased risk of for cytomegalovirus reactivation after allogeneic HSCT in T-cell depleted patients","volume":"136","author":"Molla","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcv.2026.105948_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00277-023-05509-7","article-title":"The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping","volume":"103","author":"Wu","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jcv.2026.105948_bib4","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.jcv.2026.105948_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-53168-7_6","article-title":"Herpesvirus capsid assembly and DNA packaging","volume":"223","author":"Heming","year":"2017","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"10.1016\/j.jcv.2026.105948_bib7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2026.105948_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib9","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jcv.2026.105948_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.jcv.2026.105948_bib11","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","article-title":"Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data","volume":"100","author":"Derigs","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jcv.2026.105948_bib13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2026.105948_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","article-title":"Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data","volume":"56","author":"Mori","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.jcv.2026.105948_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101769","article-title":"Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis","volume":"76","author":"Dwabe","year":"2023","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.jcv.2026.105948_bib16","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/ajt.16450","article-title":"Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection","volume":"21","author":"Cassaniti","year":"2021","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.jcv.2026.105948_bib17","unstructured":"Z. R. Time exploration of initiating letermovir for the prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Florence, Italy 2025. p. Abstract A203."},{"key":"10.1016\/j.jcv.2026.105948_bib18","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jcv.2026.105948_bib19","first-page":"529","article-title":"Chinese Medical Association. Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (\u2162)-acute graft-versus-host disease\u00a0(2020)","volume":"41","author":"Stem Cell Application Group, Chinese Society of Hematology","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jcv.2026.105948_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.jcv.2026.105948_bib21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2026.105948_bib22","unstructured":"G.A. Wells, et al., editors. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses 2014."},{"key":"10.1016\/j.jcv.2026.105948_bib23","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.jcv.2026.105948_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ajh.26094","article-title":"Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution","volume":"96","author":"Leserer","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jcv.2026.105948_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.jcv.2026.105948_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/21505594.2016.1221022","article-title":"CMV-specific immune reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Blyth","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.jcv.2026.105948_bib27","doi-asserted-by":"crossref","first-page":"169.e161","DOI":"10.1016\/j.jtct.2021.12.014","article-title":"Risk factors for early cytomegalovirus reactivation and impact of early cytomegalovirus reactivation on clinical outcomes after T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mariotti","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.jcv.2026.105948_bib28","first-page":"636","article-title":"The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Mardani","year":"2020","journal-title":"Iran. J. Microbiol"},{"key":"10.1016\/j.jcv.2026.105948_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.jcv.2026.105948_bib30","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/bjh.19451","article-title":"Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation","volume":"204","author":"Yan","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jcv.2026.105948_bib31","unstructured":"L. H A single center real-world retrospective cohort study on the prevention of cytomegalovirus infection with letermovir after HLA haploid hematopoietic stem cell transplantation [Poster presentation]. Glasgow, United Kingdom 2024."},{"key":"10.1016\/j.jcv.2026.105948_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MOH.0000000000000085","article-title":"The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation","volume":"21","author":"Ljungman","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.jcv.2026.105948_bib33","unstructured":"European Medicines Agency, Prevymis - letermovir. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevymis#ema-inpage-item-product-info\u3009, (assessed 01 November 2025)."},{"key":"10.1016\/j.jcv.2026.105948_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12185-022-03348-2","article-title":"Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis","volume":"116","author":"Mori","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jcv.2026.105948_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14377","article-title":"Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed-onset clinically significant cytomegalovirus infection after letermovir prophylaxis?","volume":"26","author":"Mendoza","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13487","article-title":"Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease","volume":"23","author":"Bansal","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcv.2026.105948_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/bloodadvances.2019000836","article-title":"Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin","volume":"4","author":"Politikos","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jcv.2026.105948_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074744","article-title":"Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV\u00ae assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications","volume":"8","author":"Tey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2026.105948_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2019.229252","article-title":"Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation","volume":"106","author":"Wagner-Drouet","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcv.2026.105948_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jtct.2021.01.024","article-title":"Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation","volume":"27","author":"Olson","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.jcv.2026.105948_bib42","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2022008047","article-title":"Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults","volume":"6","author":"Politikos","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.jcv.2026.105948_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad169","article-title":"CMV infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients","volume":"10","author":"Chavaz","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib44","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.065","article-title":"Update on cytomegalovirus infection management in allogeneic hematopoietic stem cell transplant recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)","volume":"16","author":"Pi\u00f1ana","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105948_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ejh.14117","article-title":"Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: single center Canadian data","volume":"112","author":"Pang","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jcv.2026.105948_bib46","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021006213","article-title":"Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation","volume":"6","author":"Lorentino","year":"2022","journal-title":"Blood Adv."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T17:14:34Z","timestamp":1779556474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653226000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S1386653226000375"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105948","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105948"}}